U.S. markets closed

Zymeworks Inc. (ZYME)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
5.27-0.06 (-1.13%)
At close: 04:00PM EDT
5.31 +0.04 (+0.76%)
After hours: 05:18PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Flag (Bearish)

Flag (Bearish)

Previous Close5.33
Bid5.05 x 800
Ask5.75 x 900
Day's Range5.09 - 5.36
52 Week Range4.11 - 30.18
Avg. Volume760,358
Market Cap325.129M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-4.97
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.61
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ZYME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Zymeworks Inc.
    XNCR: What does Argus have to say about XNCR?XENCOR INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Business Wire

    Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile

    VANCOUVER, British Columbia & SEATTLE, September 16, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") has recommended that Zymeworks shareholders vote FOR the Company’s plan to become a Delaware corporation (the "Redomicile").

  • Benzinga

    Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

    Zymeworks Inc (NASDAQ: ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors. The data were presented at the European Society for Medical Oncology Annual Congress. A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy. Also R

  • Business Wire

    Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware

    VANCOUVER, British Columbia & SEATTLE, September 08, 2022--Zymeworks Inc. ("Zymeworks" or the "Company") (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the proxy statement ("Proxy Statement") and related materials, dated September 2, 2022 for its special meeting of securityholders (the "Special Meeting") have been filed publicly and are being mailed to securityholders. The Special Meeting will be held on Friday, October 7